Open AccessRole of RLIP76 in doxorubicin resistance in lung cancer (Review)
Author(s) -
Rit Vatsyayan,
Pankaj Chaudhary,
Poorna Lelsani,
Preeti Singhal,
Yogesh C. Awasthi,
Sanjay Awasthi,
Sharad S. Singhal
Publication year - 2009
Publication title -
international journal of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.405
H-Index - 122
ISSN - 1019-6439
DOI - 10.3892/ijo_00000279
Subject(s) - lung cancer , chemotherapy , cancer , doxorubicin , oncogene , acquired resistance , drug resistance , molecular medicine , oncology , cancer research , biology , medicine , cell cycle , microbiology and biotechnology
Lung cancer is still a major cause of cancer deaths in spite of considerable efforts in its systemic therapy. Chemotherapy, along with local irradiation is frequently employed but as a palliative therapy. Inherent and acquired resistance in NSCLC and SCLC towards chemotherapeutic agents further makes chemotherapy an incommodious problem. The resistance mechanisms responsible for inherent DOX-resistance of NSCLC and acquired DOX-resistance in SCLC have been the subject of numerous investigations. This review will focus on the recent studies done for understanding the mechanism(s) of inherent and acquired resistance in NSCLC and SCLC and how these can be exploited for the future development of more effective novel biologic agents for the treatment of lung cancer.